Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25202788 | 1.00 | LMNA (0.58) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL23363771 | 1.00 | LMNA (0.58) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| Hydrochloric Acid SCHEMBL28216040 | 0.97 | LMNA (0.56) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL28218514 | 0.81 | LMNA (0.50) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL14568664 | 0.80 | RIPK1 (0.55) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL8377394 | 0.80 | RIPK1 (0.55) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL5610567 | 0.78 | RIPK1 (0.53) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL18256215 | 0.78 | RIPK1 (0.53) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL28983014 | 0.78 | LMNA (0.47) | LMNAKDM4EL3MBTL1AOC3RIPK1 | |
| SCHEMBL3096537 | 0.78 | LMNA (0.64) | LMNAKDM4EL3MBTL1AOC3RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103649263-A | Direct trifluoromethylation using trifluoromethane | UNIV SOUTHERN CALIFORNIA | 2014-03-19 | — | — | CN | claimed |
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240383902-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4363423-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11970498-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-04-30 | — | — | US | disclosed |
| CN-117897384-A | CDK2 inhibitors | 缆图药品公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-114728168-B | Triazole carbamate pyridylsulfonamides as LPA receptor antagonists and their use | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11932648-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| CN-117358275-A | Carbon nitride molecular junction catalyst and preparation method and application thereof | 深圳大学 | 2024-01-09 | — | — | CN | disclosed |
| US-7592486-B2 | Anhydrous fluoride salts and reagents and methods for their production | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2009-09-22 | — | — | US | disclosed |
| CN-101351451-A | Polycyclic amino acid derivatives and methods of use thereof | LEXICON GENETICS INC (US) | 2009-01-21 | — | — | CN | disclosed |
| US-6005116-A | HAVE INHIBITION ACTIVITIES AGAINST TYPE A-MONOAMINE OXIDASE; TREATING OR PREVENTING DEPRESSION, PARKINSON'S DISEASE, ALZEHEIMER'S DEMENTIA, OR CEREBROVASCULAR DEMENTIA | SANKYO COMPANY, LIMITED (JP) | 1999-12-21 | — | — | US | disclosed |
| EP-0885891-A1 | ISOXAZOLE DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0415833-B1 | Optically active fluorine-containing alcohol compounds and liquid crystal compounds therefrom | SHOWA SHELL SEKIYU (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5096613-A | OPTICALLY ACTIVE FLUORINE-CONTAINING ALCOHOL COMPOUNDS AND LIQUID CRYSTAL COMPOUNDS THEREFROM | SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) | 1992-03-17 | — | — | US | disclosed |
| EP-0415833-A2 | Optically active fluorine-containing alcohol compounds and liquid crystal compounds therefrom | Showa Shell Sekiyu Kabushiki Kaisha (JP) | 1991-03-06 | — | — | EP | disclosed |
| US-4861801-A | Treatment of depression by using a fluorophenacylamine derivative | Lafon, Laboratoire L. (FR) | 1989-08-29 | — | — | US | disclosed |
| US-4835315-A | Fluorophenacyl-amine derivatives and application thereof in therapeutics | LABORATOIRE L. LAFON (FR) | 1989-05-30 | — | — | US | disclosed |
| EP-0060954-B1 | DERIVATIVES OF FLUOROPHENACYL AMINES AND THEIR THERAPEUTIC USE | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1984-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932648-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | LMNA 2403/4885KDM4E 2160/4885L3MBTL1 2771/4885 |
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | LMNA 1879/4885KDM4E 2137/4885L3MBTL1 2693/4885 |
| US-11970498-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | LMNA 2403/4885KDM4E 2160/4885L3MBTL1 2771/4885 |
| US-20240383902-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | LMNA 2403/4885KDM4E 2160/4885L3MBTL1 2771/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | LMNA 1435/4885KDM4E 1727/4885L3MBTL1 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.